Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Chembio Diagnostics

(NASDAQ: CEMI)
Add to Portfolio
+0.81 (+13.04%)
as of Apr 7, 2020

Last 7.02
Change +0.81 (+13.04%)
Open 6.26
Prev. Close 6.21
Today's Range
5.83
7.25
52wk Range
2.25
8.00
Volume 1009895
Avg Volume 1361130
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
CEMI +13.04% +76.38% +14.52%
DJIA -0.12% -20.61% -14.27%
S&P 500 -0.16% -18.01% -8.07%

Key Statistics

Annual EPS -0.80
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 121300
Weighted Alpha -12.00
Standard Deviation +1.00
Profit Margin 12.06%
Beta 0.90

Growth Rates

YTD +53.95%
1-Year -5.34%
3-Year +3.50%
5-Year +41.14%
10-Year +237.50%

Opinion

Sell Hold Buy

Recent Headlines

Thinking about buying stock in Chembio Diagnostics,

PR Newswire via COMTEX - Wed Apr 01, 09:31AM EDT
InvestorsObserver issues critical PriceWatch Alerts for CEMI, GE, IBIO, PTON, and T.(full story)
T: 30.08 (+0.64), CEMI: 7.02 (+0.81), GE: 7.03 (-0.20), IBIO: 0.8650 (-0.0150)

Chembio Announces Launch of DPP COVID-19 Serological

GlobeNewswire via COMTEX - Tue Mar 31, 09:10PM EDT
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the U.S. launch of the rapid DPP COVID-19 serological point-of-care test for the detection of IgM(full story)
CEMI: 7.02 (+0.81)

Chembio Diagnostics Reports Inducement Award Under

GlobeNewswire via COMTEX - Fri Mar 20, 08:30AM EDT
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today reported that, in accordance with Nasdaq Listing Rule 5635(c)(4), it has granted a restricted stock unit aw(full story)
CEMI: 7.02 (+0.81)

Chembio Diagnostics Receives $4 Million Purchase Order

GlobeNewswire via COMTEX - Fri Mar 20, 08:00AM EDT
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced its receipt of a $4 million order from Bio-Manguinhos for the purchase of Chembio's DPP COVID-19 (full story)
CEMI: 7.02 (+0.81)

Chembio Diagnostics Appoints Richard Eberly As Chief

GlobeNewswire via COMTEX - Thu Mar 12, 04:46PM EDT
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment of Richard Eberly as its President and Chief Executive Officer effective March 1(full story)
CEMI: 7.02 (+0.81)